This protocol presents a common updated methodology to estimate vaccine effectiveness (VE) for COVID-19, using established health data registries in participating European Union and European Economic Area (EU/EEA) countries.
This joint guidance by the ECDC and EMCDDA aims to strengthen the evidence base for developing national strategies for preventing and controlling infections and infectious diseases among people who inject drugs.
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 4-10 February 2024 and includes updates on avian influenza, measles, MERS-CoV, COVID-19, swine influenza, respiratory virus epidemiology, Western equine encephalitis, Hepatitis E, and the Chinese New Year.
This core protocol for ECDC studies of VE against hospitalisation with SARI laboratory-confirmed with SARS-CoV-2 or with influenza, version 3.0, represents an update to the main elements for a multi-country hospital-based study of COVID-19 vaccine effectiveness in patients hospitalised with SARI, initially published as version 1.0 [5], updated to version 2.0 [6].
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 28 January - 3 February 2024 and includes updates on SARS-CoV-2 variant classification, swine influenza, human cases of co-infection with seasonal influenza and avian influenza, influenza, western equine encephalitis, and an overview of respiratory virus epidemiology in the EU/EEA.
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 21-27 January 2024 and includes updates on SARS-CoV-2, influenza, cholera, chikungunya, dengue and zika.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 14-20 January 2024 and includes updates on avian influenza, SARS-CoV-2 variant classification, an overview of respiratory viruses in the EU/EEA, mpox, measles, and Infant formula for medical purposes recalled due to possible contamination with Cronobacter sakazakii.
This generic protocol for ECDC studies describes the design and methods for a prospective multi-country cohort study of hospital-based healthcare workers (HCWs) to evaluate the effectiveness of COVID-19 vaccine in preventing laboratory-confirmed SARS-CoV-2 infection.
Influenza is a disease of public health importance due to the substantial seasonal morbidity and mortality and the high pandemic potential of its aetiologic agents, influenza viruses.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 7-13 January 2024 and includes updates on SARS-CoV-2, measles, diphtheria, Middle East respiratory syndrome coronavirus (MERS-CoV) and poliomyelitis.